ANRO
Alto Neuroscience Inc (ANRO)
Healthcare • NYSE • $24.26+0.79%
- Symbol
- ANRO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $24.26
- Daily Change
- +0.79%
- Market Cap
- $850.38M
- Trailing P/E
- N/A
- Forward P/E
- -9.28
- 52W High
- $28.44
- 52W Low
- $2.15
- Analyst Target
- $35.24
- Dividend Yield
- N/A
- Beta
- 1.65
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of a…
Company websiteResearch ANRO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.